Amgen (NASDAQ:AMGN) Releases FY 2026 Earnings Guidance

Amgen (NASDAQ:AMGN) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 22.300-23.500 for the period, compared to the consensus earnings per share estimate of 22.390. The company issued revenue guidance of $38.2 billion-$39.4 billion, compared to the consensus revenue estimate of $37.8 billion.

Analyst Upgrades and Downgrades

AMGN has been the topic of several research analyst reports. Weiss Ratings lowered shares of Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, July 15th. Freedom Capital raised shares of Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Oppenheimer boosted their target price on Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a research report on Wednesday. Robert W. Baird upped their price target on Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research note on Wednesday. Finally, Sanford C. Bernstein reiterated a “market perform” rating and issued a $345.00 price target on shares of Amgen in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $367.93.

Amgen Stock Performance

Amgen stock traded down $4.79 during mid-day trading on Thursday, reaching $403.04. 1,088,335 shares of the company’s stock were exchanged, compared to its average volume of 2,746,733. The business’s fifty day simple moving average is $359.92 and its 200 day simple moving average is $355.33. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm has a market capitalization of $217.52 billion, a PE ratio of 25.05, a P/E/G ratio of 3.95 and a beta of 0.41. Amgen has a one year low of $269.77 and a one year high of $418.40.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 132.73%. The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter in the previous year, the firm posted $6.02 EPS. Amgen’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts expect that Amgen will post 22.31 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.5%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is presently 70.15%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen delivered a significant second-quarter beat. Revenue increased 9.5% year over year to $10.05 billion, while adjusted EPS of $6.29 exceeded the $5.62 consensus estimate. The company also reported strong cash generation and growth across its product portfolio. Amgen second-quarter sales rise 9%, profit tops Street view
• Positive Sentiment: Management raised its full-year 2026 outlook. Amgen now expects revenue of $38.2 billion to $39.4 billion and adjusted EPS of $22.30 to $23.50, with the revenue midpoint above analyst expectations. Repatha and EVENITY were notable growth drivers, while 22 products posted double-digit sales growth. Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter Smash
• Positive Sentiment: Several analysts increased their price targets and retained bullish ratings. UBS raised its target to $440, TD Cowen to $452, and Scotiabank and BMO Capital Markets to $450. These revisions reflect greater confidence in Amgen’s diversified portfolio and late-stage pipeline. Amgen Price Target Raised at UBS
• Neutral Sentiment: Analyst opinion remains divided. Some firms continue to rate AMGN Buy or Outperform, but Morgan Stanley, Wells Fargo and Canaccord maintain Hold or Equal Weight ratings. Several price targets remain below the recent trading level, suggesting investors may be taking profits after the earnings-driven advance.
• Negative Sentiment: Amgen discontinued early development of an obesity-treatment candidate. Although broader product growth offset the setback, the decision reduces near-term pipeline optionality in the highly competitive weight-loss market. Amgen Lifts Outlook on Strong Drug Sales
• Negative Sentiment: Investors continue to monitor legacy-drug erosion and legal or regulatory risks. Prolia and XGEVA sales declined sharply because of biosimilar pressure, while reports of a patient-data breach and a review of Tavneos-related clinical data could create reputational, regulatory and operational uncertainty. Amgen Faces Patient Data Breach and Tavneos Review Risk

Hedge Funds Weigh In On Amgen

Large investors have recently made changes to their positions in the business. Brighton Jones LLC lifted its stake in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares during the period. Sivia Capital Partners LLC grew its position in Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after buying an additional 114 shares during the period. Schnieders Capital Management LLC. increased its holdings in Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after buying an additional 5,853 shares during the last quarter. Main Street Financial Solutions LLC boosted its stake in shares of Amgen by 11.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock worth $1,141,000 after acquiring an additional 416 shares during the last quarter. Finally, Ieq Capital LLC grew its position in shares of Amgen by 5.1% during the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock valued at $15,120,000 after acquiring an additional 2,611 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.